Internal Medicine, Rheumatology · Hemet, CA
NPI
1639374549
Since 2007
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
949 Calhoun Pl, Suite F
Hemet, CA, 92543
Phone (951) 652-5000
Groups this clinician bills Medicare through
Medicare paid, 2024
$951K
55,027 services
Medicare patients, 2024
592
Average age 73
Drug cost, 2024
$2.5M
3,177 prescriptions
Company payments, 2025
$2,975
From 22 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Amal C Mehta was code J3262 (injection, tocilizumab, 1 mg), 24,640 times for 13 patients. In total Amal C Mehta billed 55,027 services in 45 codes, and Medicare paid $951K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-12-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3262 Injection, tocilizumab, 1 mg | Office | 24,640 | 13 | $4.71 | $116K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 7,075 | 19 | $33.69 | $238K |
| J0897 Injection, denosumab, 1 mg | Office | 6,660 | 73 | $20.56 | $137K |
| 99214 Office E&M - Established | Office | 1,623 | 549 | $100.56 | $163K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,403 | 539 | $12.75 | $18K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 988 | 113 | $0.77 | $760 |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 651 | 227 | $51.09 | $33K |
| 96365 Intravenous Infusion, Hydration | Office | 231 | 67 | $52.61 | $12K |
| 96372 Injection Administration | Office | 205 | 104 | $11.70 | $2,399 |
| J3489 Injection, zoledronic acid, 1 mg | Office | 161 | 32 | $4.71 | $759 |
| 20610 Joint Injection | Office | 139 | 71 | $59.02 | $8,204 |
| 99204 Office E&M - New | Office | 118 | 118 | $133.63 | $16K |
| 96415 Chemotherapy Administration | Office | 80 | 11 | $23.08 | $1,846 |
| 98980 Care Management/Coordination | Office | 64 | 15 | $41.87 | $2,680 |
| 99213 Office E&M - Established | Office | 62 | 47 | $71.45 | $4,430 |
By year: 2022 $743K for 55,105 services; 2023 $815K for 54,015 services; 2024 $951K for 55,027 services.
Medicare prescription drug claims, 2024
In 2024, the drug Amal C Mehta prescribed most often to Medicare patients was Prednisone, with 395 prescriptions and refills. In total Amal C Mehta wrote 3,177 Medicare prescriptions that cost $2.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisone Generic | 395 | 744 | 113 | $2,756 |
| Hydroxychloroquine Sulfate Generic | 385 | 990 | 135 | $20K |
| Methotrexate Methotrexate Sodium | 341 | 880 | 130 | $12K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 145 | 145 | 22 | $2,870 |
| Gabapentin Generic | 143 | 383 | 67 | $3,971 |
| Leucovorin Calcium Generic | 138 | 310 | 51 | $2,662 |
| Prolia Denosumab | 130 | 727 | 99 | $213K |
| Allopurinol Generic | 114 | 288 | 34 | $1,099 |
| Folic Acid Generic | 104 | 306 | 47 | $703 |
| Pregabalin Generic | 98 | 232 | 32 | $4,921 |
| Leflunomide Generic | 94 | 220 | 30 | $7,986 |
| Azathioprine Generic | 55 | 133 | 17 | $2,956 |
| Alendronate Sodium Generic | 54 | 153 | 29 | $432 |
| Meloxicam Generic | 46 | 100 | 18 | $219 |
| Zoledronic Acid Zoledronic Acid/Mannitol-Water | 46 | 421 | 46 | $6,996 |
Brand drugs: 519 claims; generic drugs: 2,647 claims; opioid claims: 196.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Amal C Mehta $2,975 ($2,975 in general payments such as food, travel and fees) from 22 companies. The largest payer was Abbvie Inc. with $867.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 45 | $867 |
| UCB, Inc. UCB.BR | 17 | $424 |
| Janssen Biotech, Inc. JNJ | 16 | $218 |
| Lilly USA, LLC LLY | 10 | $198 |
| Amgen Inc. AMGN | 11 | $187 |
| GlaxoSmithKline, LLC. GSK | 7 | $171 |
| Novartis Pharmaceuticals Corporation NVS | 10 | $164 |
| AstraZeneca Pharmaceuticals LP AZN | 9 | $152 |
| Pfizer Inc. PFE | 6 | $129 |
| Galderma Laboratories, L.P. GALD.SW | 1 | $128 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.